CLAM320B2002M+A3: D9A3:D8
|
Multiple Patient Program for Lamprene (Clofazimine) for the Treatment of Non-TB Mycobacterial Infections
|
An expanded access of Lamprene (Clofazamine) to patients with Cystic Fibrosis patients with Mycobacterium infections
|
EDP-938-201
|
A Study to Evaluate EDP 938 Regimens in Infants With RSV (RSVPEDs)
|
A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in infants with RSV infection. This is a randomized, double-blind, dose ranging, placebocontrolled study in respiratory syncytial virus (RSV) among hospitalized and non-hospitalized children aged from 28 days to 24 months, assessing the safety, tolerability, pharmacokinetics, clinical outcome and antiviral activity of a 5 day treatment with EDP-938.
|
MAYFLOWERS
|
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
In this study, the investigators aim to evaluate changes in lung function in women with cystic fibrosis (CF) during pregnancy and for 2 years after pregnancy based on exposure to highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
|
| Vertex VX20-121-102 |
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation
|
The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/DIVA) in CF participants who are heterozygous for F508del and a minimal function mutation (F/MF participants).
|
| Vertex VX20-121-104 |
A Phase 3 Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects with Cystic Fibrosis Who are Homozygous or Heterozygous for the F508del Mutation.
|
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.
|
| AR-501 |
SAD and MAD of Inhaled AR501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects |
This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis (CF) subjects. |
BMX-04-001
|
Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection
|
This is a Phase 1b/2a study with the primary objective to determine if BX004-A is safe and tolerable. Exploratory objectives include whether BX004-A reduces sputum Pseudomonas aeruginosa (PsA) bacterial load in CF subjects with chronic PsA pulmonary infection.
|
STOP360-IP-22
|
Standardizing Treatments for Pulmonary Exacerbations: A platform for evaluating treatment decisions to improve outcomes |
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs medical intervention. Both doctors and CF patients are trying to understand the best way to treat pulmonary exacerbations |
